Derma Sciences — Merger or Acquisition (August 2016)
17 slides from Derma Sciences's merger presentation, Aug 1, 2016
Slide 1: Acquisition of BioD & FAD Divestiture
July 28, 2016 Acquisition of BioD & FAD Divestiture
Slide 2: Forward-Looking Statements
Forward-Looking Statement-Looking Statements Statements contained in this presentation that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” believe, anticipate, intend, coul
Slide 3: Introduction & Call Overview
Introduction & Call Overview Todays speakers - Stephen T. Wills, Derma Sciences Executive Chairman and Interim Principal Executive Officer - Russell Olsen, BioD Chief Executive Officer Todays topics - Acquisition of BioD, LLC - Concurrent $2.0 million private placement - Sale of First Aid Division f
Slide 4: BioD Overview
BioD Overview Privately-held, fully integrated biotechnology company headquartered in Memphis, Tenn. Develops and commercializes novel biologic products derived from placental / birth tissues Products are used in a broad range of clinical applications including the treatment of complex chronic wound
Slide 5: A Powerful Strategic Business Fit
A Powerful Strategic Business Fit The acquisition of BioD solidifies Derma Sciences as a leading provider of advanced wound care (AWC) and regenerative medicine products - Consistent with Derma Sciencesgrowth strategy to increase AWC segment revenues and leverage managements AWC expertise - Increase
Slide 6: The BioD Market Opportunity
The BioD Market Opportunity ($ in billions) CHANNEL PARTNERS ($0.8) ADVANCED WOUND CARE BioD markets its products through a network of 235 independent sales reps and 7 direct sales reps to the following markets: - Orthopedic / Spine - Ocular - Urology - Plastics In addition, BioD provides products f
Slide 7: Cryopreserved liquid allograft
Cryopreserved liquid allograft Human placental tissue-derived liquid allograft that provides a structural matrix to facilitate tissue regeneration Indicated for the treatment of localized tissue voids and defects, and areas of inflammation Can be injected or applied directly to the surgical site Cry
Slide 8: Resorbable adhesion barrier
Resorbable adhesion barrier Moist and fully hydrated Packaged in saline and offered in several different sizes, which may be cut in the clinical setting Shelf life of five years Clinical applications include dura protection, interspinal muscle protection, laminectomy, craniotomy, nerve bundle protec
Slide 9: BioD Product Pipeline
BioD Product Pipeline Urology Prostatectomy 2016 2017 2018 Advanced Wound Care Human Placental Matrix Ophthalmology Dry Eye Neurology Cranioplasty Spine Chiari Graft Oculoplasty Tarsal Graft A TISSUE REGENERATION COMPANY 9
Slide 10: BioD Transaction Structure
BioD Transaction Structure Upfront consideration of $21.3 million, to be paid 65% in cash and 35% through the issuance of 1.8 million Derma Sciences shares Contingent considerations - Potential product regulatory milestone payments in 2016 and/or 2017 of up to $30.0 million in aggregate (payable in
Slide 11: FAD Divestiture Overview
FAD Divestiture Overview Sale of the First Aid Division to Dukal Corp., a privately held supplier of best-in-class disposable medical products and patient-care items Total purchase price of approximately $12.2 million, including inventory - $9.5 million will be paid in cash to Derma Sciences at clos
Slide 12: Derma Sciences AWC Business Segments
Derma Sciences AWC Business Segments Derma Sciences AWC BioD Proprietary technologies for treating chronic wounds and burns Grew year-over-year by 9.6% in 2015 2015 Revenues: $41.8 million 2010-2015 Revenue CAGR: 29%(1) Gross Margins: 50% Sales Model: Direct sales organizations in the U.S., U.K. and
Slide 13: Enhanced Advanced Wound Care Provider
Enhanced Advanced Wound Care Provider AWC Revenue ($ in millions) $0 $10 $20 $30 $40 $50 $60 $70 2009 2010 2011 2012 2013 2014 2015 2015 PF AWC Revenue % Growth % of Total Revenue $7.6 $11.6 $15.9 $24.8 $33.9 $38.1 $41.8 $60.4 52.3% 37.3% 55.9% 36.6% 12.3% 9.6% N.M. 15.7% 20.5% 25.4% 34.2% 42.6% 45.
Slide 14: Pro Forma Product Mix and Gross Margin Expansion
Pro Forma Product Mix and Gross Margin Expansion ($ in millions) Derma Standalone Revenue & Gross Margin Pro Forma Revenue & Gross Margin(1) 0% 10% 20% 30% 40% 50% 60% $0$25$50$75$1002014A2015A2016EAdvanced Wound CareTraditional Wound CareGross Margin 0% 10% 20% 30% 40% 50% 60% $0$25$50$75$100Standa
Slide 15: Sale of Comvita Shares
Sale of Comvita Shares During 2013 and 2014 Derma Sciences invested $8.5 million in Comvita Limited to support their acquisition of apiaries and their harvest modernization strategy, and to ensure a reliable supply of medical-grade leptospermum honey for the MEDIHONEY product line In mid-May Derma S
Slide 16: Pro Forma Cash & Revenue by Division
Pro Forma Cash & Revenue by Division Derma Sciences pro forma cash, short-term investments and marketable securities are $57.4 million(1), as follows: $44.0 million cash and short-term investments as of June 30, 2016 (inclusive of $7.6 million in proceeds from the Comvita stock sale in May) + $15.8
Slide 17: Leveraging Assets, Supplementing Organic Growth
Leveraging Assets, Supplementing Organic Growth Focus and Priorities Leverage managements expertise in advanced wound care Primary growth emphasis on improving AWC vs TWC product mix and expanding gross margins Transformational or high-growth mid-size opportunities + tuck-in opportunities EBITDA acc